DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Pevonedistat

Generic Name: Pevonedistat

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅N_₅O_₄S

CAS Number: 905579-51-3

Unique Ingredient Identifier: S3AZD8D215

Overview

Pevonedistat has been used in trials studying the treatment of Lymphoma, Solid Tumors, Multiple Myeloma, Hodgkin Lymphoma, and Metastatic Melanoma, among others.

Background

Pevonedistat has been used in trials studying the treatment of Lymphoma, Solid Tumors, Multiple Myeloma, Hodgkin Lymphoma, and Metastatic Melanoma, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes

Phase 2

Withdrawn

Posted: 2021/08/02

Sponsor:Takeda

Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor

Phase 1

Terminated

Posted: 2021/03/16

Sponsor:M.D. Anderson Cancer...

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

Phase 2

Completed

Posted: 2021/01/19

Sponsor:

University of Leipzi...

Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes

Posted: 2020/07/23

Sponsor:Takeda

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

Phase 2

Active, not recruiting

Posted: 2020/02/12

Sponsor:Takeda

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

FDA Approves Takeda's Exkivity as First Oral Therapy for EGFR Exon20 NSCLC

3 months ago

Takeda's Exkivity (mobocertinib) receives FDA approval as the first oral therapy specifically designed for NSCLC patients with EGFR exon20 insertion mutations after chemotherapy.

Advancements in Higher-Risk MDS Treatment Strategies Explored

8 months ago

Allogeneic transplantation remains the only curative option for high-risk myelodysplastic syndrome (HR-MDS) patients, but post-transplant relapse is still a problem.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy